U2Bio Co., Ltd.
U2Bio Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was founded in 2009 and is headquartered in Seoul, South Korea.
U2Bio Co., Ltd. (221800) - Total Liabilities
Latest total liabilities as of March 2025: ₩10.25 Billion KRW
Based on the latest financial reports, U2Bio Co., Ltd. (221800) has total liabilities worth ₩10.25 Billion KRW as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
U2Bio Co., Ltd. - Total Liabilities Trend (2022–2024)
This chart illustrates how U2Bio Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
U2Bio Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of U2Bio Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asian Granito India Limited
NSE:ASIANTILES
|
India | ₹8.20 Billion |
|
Metropolitan Kentjana Tbk
JK:MKPI
|
Indonesia | Rp2.24 Trillion |
|
JTL Industries Ltd
NSE:JTLIND
|
India | ₹2.74 Billion |
|
Dimeco Inc
OTCQX:DIMC
|
USA | $1.00 Billion |
|
Charlton Aria Acquisition Corporation Units
NASDAQ:CHARU
|
USA | $1.74 Million |
|
Semperit AG Holding
LSE:0G29
|
UK | €466.29 Million |
|
Simplex Infrastructures Limited
NSE:SIMPLEXINF
|
India | ₹33.03 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down U2Bio Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how U2Bio Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for U2Bio Co., Ltd. (2022–2024)
The table below shows the annual total liabilities of U2Bio Co., Ltd. from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩10.56 Billion | -5.82% |
| 2023-12-31 | ₩11.21 Billion | -34.78% |
| 2022-12-31 | ₩17.18 Billion | -- |